Get the Stockscreener App
67.49
1.26%
0.84
Merus N V stock is traded at $67.49, with a volume of 697.98K.
It is up +1.26% in the last 24 hours and up +6.69% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$66.65
Open:
$66.28
24h Volume:
697.98K
Relative Volume:
0.66
Market Cap:
$5.10B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-17.09
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
+0.36%
1M Performance:
+6.69%
6M Performance:
+42.47%
1Y Performance:
+26.50%
1-Day Range:
$66.18
$68.00
1-Week Range:
$62.63
$68.00
52-Week Range:
$33.19
$68.00
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
67.49 | 4.99B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Piper Sandler | Overweight |
| Feb-07-25 | Initiated | Wells Fargo | Overweight |
| Nov-21-24 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Mar-28-24 | Initiated | Truist | Buy |
| Mar-04-24 | Reiterated | Needham | Buy |
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
Merus N.V. Reports Q2 2025 Financial Results - TipRanks
Merus N.V. stock trendline breakdownQuarterly Risk Review & Daily Price Action Insights - Newser
Momentum divergence signals in Merus N.V. chartJuly 2025 Volume & Growth Focused Stock Reports - Newser
Can volume confirm reversal in Merus N.V.Weekly Stock Analysis & Free Weekly Watchlist of Top Performers - Newser
Merus N.V. stock chart pattern explainedGap Down & High Yield Equity Trading Tips - Newser
How to escape a deep drawdown in Merus N.V.2025 Technical Overview & Free Weekly Watchlist of Top Performers - Newser
Using Bollinger Bands to evaluate Merus N.V.July 2025 Review & Weekly Breakout Watchlists - Newser
News impact scoring models applied to Merus N.V.Weekly Profit Summary & Fast Moving Stock Watchlists - Newser
US Bancorp DE Increases Stock Position in Merus N.V. $MRUS - Defense World
US Bancorp DE Boosts Holdings in Merus N.V. $MRUS - Defense World
Why Merus N.V. stock attracts strong analyst attentionRate Cut & Daily Profit Focused Screening - 선데이타임즈
Merus N.V.’s volatility index tracking explained2025 Earnings Surprises & Low Drawdown Investment Strategies - Newser
Using Python tools to backtest Merus N.V. strategiesPortfolio Value Report & Long-Term Investment Growth Plans - Newser
Is Merus N.V. reversing from oversold territoryTrade Analysis Summary & Scalable Portfolio Growth Ideas - Newser
Visual analytics tools that track Merus N.V. performanceTrade Risk Report & Safe Entry Point Identification - Newser
Is Merus N.V. attractive for institutional investors2025 Institutional Moves & Real-Time Buy Zone Alerts - classian.co.kr
Reversal indicators forming on Merus N.V. stock2025 Risk Factors & Free Long-Term Investment Growth Plans - Newser
Applying Wyckoff theory to Merus N.V. stockJuly 2025 Recap & Verified Swing Trading Watchlist - Newser
PNC Financial Services Group Inc. Acquires 1,340 Shares of Merus N.V. (NASDAQ:MRUS) - Defense World
Is this a good reentry point in Merus N.V.2025 Price Action Summary & Safe Entry Trade Reports - Newser
What Fibonacci levels say about Merus N.V. reboundJuly 2025 Sector Moves & Stepwise Entry and Exit Trade Signals - Newser
Advanced analytics toolkit walkthrough for Merus N.V.Analyst Upgrade & Risk Controlled Daily Trade Plans - Newser
Regression analysis insights on Merus N.V. performanceGap Down & Detailed Earnings Play Alerts - Newser
Comparing Merus N.V. in custom built stock radarsQuarterly Earnings Summary & Real-Time Volume Analysis - Newser
Multi asset correlation models including Merus N.V.2025 Institutional Moves & Fast Exit Strategy with Risk Control - Newser
Will earnings trigger a reversal in Merus N.V.2025 Market Overview & Smart Investment Allocation Insights - Newser
Merus N.V. Recovery Likely Here’s What Data ShowsEarnings Recap Report & Free Fast Gain Swing Trade Alerts - kangso.co.kr
Merus N.V. Moves Into Bullish Territory Based on MACDJuly 2025 Setups & Low Risk High Win Rate Stock Picks - thegnnews.com
Analysts' Top Picks in Healthcare: Merus, AdaptHealth, and Travere Therapeutics - AInvest
The Bull Case For Merus (MRUS) Could Change Following Surging Revenue and Escalating Losses in Q2 2025 - simplywall.st
Merus NV stock hits all-time high at 67.59 USD By Investing.com - Investing.com South Africa
Merus NV stock hits all-time high at 67.59 USD - Investing.com
Leerink Partnrs Comments on Merus’ Q3 Earnings (NASDAQ:MRUS) - Defense World
What is HC Wainwright’s Estimate for Merus Q3 Earnings? - Defense World
How Rising Losses and Strong Cash Reserves at Merus (MRUS) Have Changed Its Investment Story - simplywall.st
Merus N.V. (NASDAQ:MRUS) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Is Merus' (MRUS) Rising Revenue and Widening Losses Changing Its Investment Story? - simplywall.st
Zurcher Kantonalbank Zurich Cantonalbank Has $563,000 Stock Holdings in Merus N.V. (NASDAQ:MRUS) - Defense World
Bank of America Securities Maintained a Buy Rating on Merus N.V (MRUS) - MSN
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference - The Manila Times
Merus Showcases Revolutionary Cancer Treatment Platform at Major Growth Conference: CEO Presentation Details - Stock Titan
Merus to sustain operations through 2028 with $892 million in cash and equivalents. - AInvest
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update - The Manila Times
Merus sees cash runway at least into 2028 - TipRanks
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Merus reports Q2 EPS ($2.23), consensus ($1.15) - TipRanks
Merus (MRUS) Q2 Revenue Falls Short of Expectations, Exciting Cl - GuruFocus
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Envestnet Asset Management Inc. Makes New $589,000 Investment in Merus N.V. (NASDAQ:MRUS) - Defense World
Merus N.V. Forms Bullish Flag — Upside AheadTop Performing Stock Insights Released Daily - metal.it
Merus Awards Massive $15.7M Stock Options Package to Key New Hires in Oncology Push - Stock Titan
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merus N V Stock (MRUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Silverman Peter B. | COO & GC |
Jul 17 '25 |
Sale |
60.00 |
25,000 |
1,500,000 |
0 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):